Intravenous vinorelbine (NVBiv) on D1 switch to oral
vinorelbine (NVBo) on D8 in combination with carboplatin
(CBDCA) as first line treatment in advanced non-small lung
cancer patients: final results of a prospective study in
nonrandomized population

a 2011

Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population

SKŘIČKOVÁ, Jana, Jana KEILOVÁ, Tereza JANASKOVÁ, Vítězslav KOLEK, Marcela TOMÍŠKOVÁ et. al.

Basic information

Original name

Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population

Authors

SKŘIČKOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Jana KEILOVÁ (203 Czech Republic), Tereza JANASKOVÁ (203 Czech Republic), Vítězslav KOLEK (203 Czech Republic), Marcela TOMÍŠKOVÁ (203 Czech Republic), Lenka BABIČKOVÁ (203 Czech Republic), Bohdan KADLEC (203 Czech Republic), Yvona GRYGARKOVÁ (203 Czech Republic), Jiří BARTOŠ (203 Czech Republic), Jan CHALUPA (203 Czech Republic), Tomáš TŘASOŇ (203 Czech Republic), Jiří GRUNA (203 Czech Republic), Jana ŠVECOVÁ (203 Czech Republic) and Helena COUPKOVÁ (203 Czech Republic)

Edition

Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer, 2011

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.661

RIV identification code

RIV/00216224:14110/11:00052790

Organization unit

Faculty of Medicine

ISSN

UT WoS

000291769801017

Keywords in English

vinorelbin; Advanced NSCLC; First line treatment

Změněno: 15/9/2011 13:54, Mgr. Michal Petr

Abstract

V originále

Lung cancer is the leading cause of cancer mortality in the Czech Republic. Approximately 80% of cases are NSCLC and 65% of patients have advanced disease at the time of diagnosis. For patients with advanced NSCLC and preserved functional status, the standard therapy is a double agent platinum-based chemotherapy. Most patients who receive first-line chemotherapy experience disease progression within 3 to 6 months of initiating therapy and the median survival time observed is 8 to 10 months. In this situation, there is a need to find effective therapeutic regimen with an administration as simple as possible and the most favorable toxicity profile. The purpose of this trial was to evaluate the activity and feasibility of CBDCA together with NVBiv and NVBo.

Citovat

SKŘIČKOVÁ, Jana, Jana KEILOVÁ, Tereza JANASKOVÁ, Vítězslav KOLEK, Marcela TOMÍŠKOVÁ, Lenka BABIČKOVÁ, Bohdan KADLEC, Yvona GRYGARKOVÁ, Jiří BARTOŠ, Jan CHALUPA, Tomáš TŘASOŇ, Jiří GRUNA, Jana ŠVECOVÁ and Helena COUPKOVÁ. Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population (Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic). In Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer. 2011. ISSN 1556-0864.

@proceedings{946858,
   author = {Skřičková, Jana and Keilová, Jana and Janasková, Tereza and Kolek, Vítězslav and Tomíšková, Marcela and Babičková, Lenka and Kadlec, Bohdan and Grygarková, Yvona and Bartoš, Jiří and Chalupa, Jan and Třasoň, Tomáš and Gruna, Jiří and Švecová, Jana and Coupková, Helena},
   booktitle = {Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer},
   keywords = {vinorelbin; Advanced NSCLC; First line treatment},
   language = {eng},
   title = {Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population},
   year = {2011}
}

TY  - CONF
ID  - 946858
AU  - Skřičková, Jana - Keilová, Jana - Janasková, Tereza - Kolek, Vítězslav - Tomíšková, Marcela - Babičková, Lenka - Kadlec, Bohdan - Grygarková, Yvona - Bartoš, Jiří - Chalupa, Jan - Třasoň, Tomáš - Gruna, Jiří - Švecová, Jana - Coupková, Helena
PY  - 2011
TI  - Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population
KW  - vinorelbin
KW  - Advanced NSCLC
KW  - First line treatment
N2  - Lung cancer is the leading cause of cancer mortality in the Czech Republic. Approximately 80% of cases are NSCLC and 65% of patients have advanced disease at the time of diagnosis. For patients with advanced NSCLC and preserved functional status, the standard therapy is a double agent platinum-based chemotherapy. Most patients who receive first-line chemotherapy experience disease progression within 3 to 6 months of initiating therapy and the median survival time observed is 8 to 10 months. In this situation, there is a need to find effective therapeutic regimen with an administration as simple as possible and the most favorable toxicity profile. The purpose of this trial was to evaluate the activity and feasibility of CBDCA together with NVBiv and NVBo.
ER  -

SKŘIČKOVÁ, Jana, Jana KEILOVÁ, Tereza JANASKOVÁ, Vítězslav KOLEK, Marcela TOMÍŠKOVÁ, Lenka BABIČKOVÁ, Bohdan KADLEC, Yvona GRYGARKOVÁ, Jiří BARTOŠ, Jan CHALUPA, Tomáš TŘASOŇ, Jiří GRUNA, Jana ŠVECOVÁ and Helena COUPKOVÁ. Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population (Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic). In \textit{Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer}. 2011. ISSN~1556-0864.

Detailed Information on Publication Record